Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.76
(2.57%)
INR 16.76
(2.57%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.59 Billion INR | 18.38% |
| 2022 | 2.22 Billion INR | 2.14% |
| 2021 | 2.17 Billion INR | -8.98% |
| 2020 | 2.39 Billion INR | 19.61% |
| 2019 | 2 Billion INR | 9.95% |
| 2018 | 1.81 Billion INR | 18.15% |
| 2017 | 1.54 Billion INR | -14.17% |
| 2016 | 1.79 Billion INR | -2.42% |
| 2015 | 1.83 Billion INR | 6.06% |
| 2014 | 1.73 Billion INR | 14.61% |
| 2013 | 1.51 Billion INR | 31.61% |
| 2012 | 1.14 Billion INR | -2.96% |
| 2011 | 1.18 Billion INR | 55.2% |
| 2010 | 763.23 Million INR | -10.63% |
| 2009 | 854.06 Million INR | 48.37% |
| 2008 | 575.63 Million INR | -15.15% |
| 2007 | 678.43 Million INR | 17.72% |
| 2006 | 576.33 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 872.55 Million INR | 17.01% |
| 2023 Q4 | 745.72 Million INR | 14.48% |
| 2023 Q3 | 651.39 Million INR | 2.04% |
| 2023 Q2 | 638.38 Million INR | 6.69% |
| 2023 Q1 | 598.35 Million INR | 1.05% |
| 2023 FY | 2.63 Billion INR | 18.38% |
| 2022 Q1 | 514 Million INR | -8.85% |
| 2022 FY | 2.22 Billion INR | 2.14% |
| 2022 Q4 | 592.11 Million INR | 3.19% |
| 2022 Q3 | 573.82 Million INR | 5.31% |
| 2022 Q2 | 544.91 Million INR | 6.01% |
| 2021 Q4 | 563.92 Million INR | -1.46% |
| 2021 Q2 | 529.36 Million INR | 3.25% |
| 2021 Q3 | 572.26 Million INR | 8.1% |
| 2021 FY | 2.17 Billion INR | -8.98% |
| 2021 Q1 | 512.69 Million INR | -14.63% |
| 2020 Q3 | 841.69 Million INR | 27.81% |
| 2020 Q4 | 600.53 Million INR | -28.65% |
| 2020 FY | 2.39 Billion INR | 19.61% |
| 2020 Q1 | 292.4 Million INR | -22.24% |
| 2020 Q2 | 658.53 Million INR | 125.22% |
| 2019 Q4 | 376.03 Million INR | -28.13% |
| 2019 Q1 | 538.39 Million INR | -4.6% |
| 2019 Q2 | 563.13 Million INR | 4.6% |
| 2019 Q3 | 523.21 Million INR | -7.09% |
| 2019 FY | 2 Billion INR | 9.95% |
| 2018 Q1 | 329.16 Million INR | -16.08% |
| 2018 FY | 1.81 Billion INR | 18.15% |
| 2018 Q4 | 564.37 Million INR | 18.41% |
| 2018 Q3 | 476.62 Million INR | 6.03% |
| 2018 Q2 | 449.52 Million INR | 36.56% |
| 2017 Q2 | 389.16 Million INR | -5.14% |
| 2017 FY | 1.54 Billion INR | -14.17% |
| 2017 Q4 | 392.25 Million INR | -0.6% |
| 2017 Q3 | 394.63 Million INR | 1.41% |
| 2017 Q1 | 410.25 Million INR | -15.84% |
| 2016 Q1 | 434.93 Million INR | -9.12% |
| 2016 FY | 1.79 Billion INR | -2.42% |
| 2016 Q4 | 487.49 Million INR | 0.0% |
| 2015 Q3 | 458.85 Million INR | -8.44% |
| 2015 Q1 | 400.37 Million INR | -7.23% |
| 2015 Q2 | 501.16 Million INR | 25.17% |
| 2015 FY | 1.83 Billion INR | 6.06% |
| 2015 Q4 | 478.57 Million INR | 4.3% |
| 2014 Q3 | 498.49 Million INR | 7.68% |
| 2014 Q1 | 340.87 Million INR | -20.27% |
| 2014 Q2 | 462.96 Million INR | 35.82% |
| 2014 FY | 1.73 Billion INR | 14.61% |
| 2014 Q4 | 431.57 Million INR | -13.42% |
| 2013 Q2 | 374.79 Million INR | 23.28% |
| 2013 Q4 | 427.52 Million INR | 5.16% |
| 2013 FY | 1.51 Billion INR | 31.61% |
| 2013 Q1 | 304.02 Million INR | -14.97% |
| 2013 Q3 | 406.54 Million INR | 8.47% |
| 2012 Q4 | 357.53 Million INR | 4.75% |
| 2012 Q2 | 346.56 Million INR | 205.37% |
| 2012 Q3 | 341.33 Million INR | -1.51% |
| 2012 Q1 | 113.49 Million INR | 0.0% |
| 2012 FY | 1.14 Billion INR | -2.96% |
| 2011 FY | 1.18 Billion INR | 55.2% |
| 2010 FY | 763.23 Million INR | -10.63% |
| 2009 FY | 854.06 Million INR | 48.37% |
| 2008 FY | 575.63 Million INR | -15.15% |
| 2007 FY | 678.43 Million INR | 17.72% |
| 2006 FY | 576.33 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.465% |
| NATCO Pharma Limited | 40.02 Billion INR | 93.522% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 75.342% |
| Achyut Healthcare Limited | 61.36 Million INR | -4124.348% |
| Ajanta Pharma Limited | 42.08 Billion INR | 93.84% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.953% |
| Alpa Laboratories Limited | 1.08 Billion INR | -138.409% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 95.759% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 79.989% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.097% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 45.24% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 66.343% |
| Brooks Laboratories Limited | 794.86 Million INR | -226.15% |
| Divi's Laboratories Limited | 78.45 Billion INR | 96.695% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.071% |
| Eris Lifesciences Limited | 20.09 Billion INR | 87.097% |
| FDC Limited | 19.42 Billion INR | 86.657% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 97.805% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 88.646% |
| Granules India Limited | 45.06 Billion INR | 94.247% |
| Gufic Biosciences Limited | 8.06 Billion INR | 67.862% |
| Hester Biosciences Limited | 3.04 Billion INR | 14.875% |
| Indoco Remedies Limited | 17.89 Billion INR | 85.513% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 79.761% |
| Ipca Laboratories Limited | 76.22 Billion INR | 96.599% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -24.217% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -414.154% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -148.473% |
| Laurus Labs Limited | 50.01 Billion INR | 94.817% |
| Lupin Limited | 200.1 Billion INR | 98.704% |
| Mankind Pharma Limited | 103.34 Billion INR | 97.492% |
| Medicamen Biotech Limited | 1.79 Billion INR | -44.582% |
| Medico Remedies Limited | 1.44 Billion INR | -78.887% |
| Megasoft Limited | 373.95 Million INR | -593.253% |
| Piramal Pharma Limited | 81.71 Billion INR | 96.827% |
| RPG Life Sciences Limited | 5.82 Billion INR | 55.46% |
| Sigachi Industries Limited | 3.98 Billion INR | 35.019% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -243.164% |
| Unichem Laboratories Limited | 16.57 Billion INR | 84.359% |
| Wanbury Limited | 5.75 Billion INR | 54.965% |
| Windlas Biotech Limited | 6.3 Billion INR | 58.913% |
| ZIM Laboratories Limited | 3.67 Billion INR | 29.443% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.637% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 77.482% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 38.456% |
| Bal Pharma Limited | 3.39 Billion INR | 23.576% |
| Strides Pharma Science Limited | 40.51 Billion INR | 93.601% |
| Venus Remedies Limited | 5.91 Billion INR | 56.168% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 85.721% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 84.606% |
| Shilpa Medicare Limited | 11.51 Billion INR | 77.488% |
| Aarti Drugs Limited | 25.28 Billion INR | 89.747% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 87.766% |
| Suven Life Sciences Limited | 116.92 Million INR | -2117.106% |
| Ind-Swift Limited | 5.02 Billion INR | 48.406% |
| Valiant Laboratories Limited | 1.82 Billion INR | -42.397% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 92.559% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 79.066% |
| Themis Medicare Limited | 3.81 Billion INR | 32.093% |
| Hikal Limited | 17.84 Billion INR | 85.473% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 97.556% |
| Sequent Scientific Limited | 13.69 Billion INR | 81.073% |
| Novartis India Limited | 3.35 Billion INR | 22.63% |
| Wockhardt Limited | 27.89 Billion INR | 90.705% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 96.132% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -547.539% |
| Neuland Laboratories Limited | 15.58 Billion INR | 83.367% |
| Morepen Laboratories Limited | 17.01 Billion INR | 84.767% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -67.934% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 29.667% |